ReviewVaccines2021
Cervical Cancer Protection in Japan: Where Are We?
Review in Vaccines, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 27 citations in OpenAlex.
- AI Chatbot Use for Human Papillomavirus Vaccine Literacy in Japan: A Randomized Clinical Trial.JAMA network open · 2026Trial
- Cemiplimab monotherapy in Japanese patients with recurrent or metastatic cervical cancer.Cancer medicine · 2024Trial
- Global and Regional Diagnostic Results of Progress Toward Cervical Cancer Elimination, According to the WHO Strategy: A Systematic Literature Review with Narrative SynthesisDiagnostics (Basel, Switzerland) · 2026Review
- Article
- Burden and Risk Factor Patterns of Reproductive System Tumors and Non-Tumor Diseases Among Asian Women, 1990-2021: Evidence from the GBD Study.International journal of women's health · 2026Article
- The effects of human papillomavirus vaccination in Japan.Human vaccines & immunotherapeutics · 2025Article
- Lack of knowledge, not vaccine hesitancy, is the main cause of low human papilloma virus vaccination rate among systemic lupus erythematosus patients in Japan after suspension of proactive recommendation: Analysis of a patients' survey.The journal of obstetrics and gynaecology research · 2025Article
- Cost-effectiveness analysis of 9-valent human papillomavirus vaccine combined with screening for cervical cancer in Japan.International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics · 2025Article
- A questionnaire survey of cervical and breast cancer screening among female employees and employees' spouses.Scientific reports · 2025Article
- Understanding Human Papillomavirus Vaccination Hesitancy in Japan Using Social Media: Content Analysis.Journal of medical Internet research · 2025Article
- Clinical impact of age‑specific distribution of combination patterns of cytology and high‑risk HPV status on cervical intraepithelial neoplasia grade 2 or more.Oncology letters · 2023Article
- Disparities among Japanese municipalities in recommendations for routine and catch-up HPV vaccinations.Cancer science · 2023Article
- Mailing human papillomavirus self-sampling kits to women under-screened for cervical cancer improved detection in cervical cancer screening in a general population study in Japan.BMC public health · 2023Article
- A Review of Parental Vaccine Hesitancy for Human Papillomavirus in Japan.Journal of clinical medicine · 2023Review
- Can Catch-Up Vaccinations Fill the Void Left by Suspension of the Governmental Recommendation of HPV Vaccine in Japan?Vaccines · 2022Article
- Article
- Effect of Different Educational Interventions on Knowledge of HPV Vaccination and Cervical Cancer among Young Women: A Preliminary Report.International journal of environmental research and public health · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
19 authors at 3 institutions in 1 country.
Funding
Abstract
In Japan, government subsidies for human papillomavirus (HPV) vaccination of girls aged 13-16 commenced in 2010. By early 2013, vaccination had become a widely accepted national immunization program. However, in June of 2013, the Ministry of Health, Labor, and Welfare (MHLW), the government's lead agency, suspended its recommendation for vaccination in response to reports of adverse vaccine events. The rate of HPV vaccination quickly dropped from 70% to almost zero, where it has lingered for eight years. In 2020, a new 9-valent HPV vaccine was licensed in Japan. The momentum seemed to be building for the resumption of HPV vaccinations, yet Japanese mothers remain widely hesitant about vaccinating their daughters, despite the well-proven safety and efficacy of the HPV vaccines. The Japanese government and our educational and medical institutions must work harder as a team to inform our parents and their children about the life-saving benefits of the HPV vaccine, and at the same time, we must respond to all their concerns and questions. The vaccine hesitancy of unvaccinated women born in 2000 and thereafter is a natural consequence of the suspension of the government's recommendation. We must also take every possible measure to reduce the significant risk for cervical cancer these women have.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.